Gujarat Kidney & Super Speciality Limited (NSE: GKSL, BSE: 544666) is a Vadodara, Gujarat-based company in the Hospitals and Healthcare Centers industry. With a market capitalisation of ₹1,233 Cr, it ranks #1,485 by market cap among the 6,197 Indian listed companies on FinBizNet, and #22 of 46 in Hospitals and Healthcare Centers. At ₹150.54 (as of 19 Nov 2026), the share price is 28.2% below its 52-week high of ₹209.80 and 53.1% above its 52-week low of ₹98.36.
| Current Price | ₹150.54 |
|---|---|
| Market Cap | ₹1,233 Cr |
| NSE Symbol | GKSL |
| BSE Code | 544666 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Facilities > Hospitals and Healthcare Centers |
| P/E Ratio | 62.8 |
| Return on Equity | 6.60% |
| Return on Assets | 7.88% |
| 52-Week Range | ₹98.36 – ₹209.80 |
| 3-Month Price Change | -4.3% |
| Beta (1Y) | 0.53 |
| Headquarters | Vadodara, Gujarat |
| Website | www.gujaratsuperspecialityhospital.com |
| Revenue | ₹38 Cr |
|---|---|
| Net Profit | ₹7 Cr |
| Net Margin | 17.3% |
| EPS (Basic) | ₹0.74 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Gujarat Kidney & Super Speciality Limited reported revenue of ₹38 Cr in Q2 FY27, up 194.6% from ₹13 Cr in Q2 FY26 and up 11.1% from ₹34 Cr in Q1 FY27. It posted a net profit of ₹7 Cr for the quarter, against a net profit of ₹3 Cr in Q2 FY26 (up 129.2%). Across the 5 quarters from Q2 FY26 to Q2 FY27, quarterly revenue ranged from ₹13 Cr (Q2 FY26) to ₹38 Cr (Q2 FY27). The company was profitable in each of these 5 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹38 Cr | ₹7 Cr | 17.3% |
| Q1 FY27 | ₹34 Cr | ₹5 Cr | 15.5% |
| Q4 FY26 | ₹31 Cr | ₹5 Cr | 15.8% |
| Q3 FY26 | ₹23 Cr | ₹4 Cr | 16.0% |
| Q2 FY26 | ₹13 Cr | ₹3 Cr | 22.3% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 71.45% of Gujarat Kidney & Super Speciality Limited's shares as of Sept 2026, unchanged from Dec 2025. Delivery averaged 54.2% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).
Gujarat Kidney and Super Speciality Limited operates multi-specialty and super-specialty hospitals. It provides treatment for Oncology, Neurology, Gastroenterology, Urology, Nephrology, and Physiotherapy. It also offers Renal Surgery, Vascular Surgery, Gynecology and obstetrics, Robotic Surgery, Bariatric Surgery, Laparoscopic Surgery, Endocrine Surgery, Neurosurgery, and Joint Replacement services. Its facilities include intensive care unit, patient counselling, operation theatres, and dialysis center. Gujarat Kidney And Super Speciality Limited was founded in 2014 and is headquartered in Vadodara, India.
1. Dealing in Trading of Pharma Goods-This segment operates multi-specialty and super-specialty hospitals. 2. NA-NA 3. NA-NA 4. NA-NA
1. Dealing in Trading of Pharma Goods-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹1,23,712 Cr | 63 | 21.50% | ₹7,615 Cr | +17.4% |
| Max Healthcare Institute Ltd | ₹91,978 Cr | 63.9 | 14.33% | ₹2,569 Cr | -5.2% |
| Manipal Health Enterprises Ltd | ₹89,110 Cr | 88.4 | — | ₹3,399 Cr | — |
| Aster Dm Healthcare Limited (Asterdm) | ₹63,041 Cr | 97.6 | 10.07% | ₹2,829 Cr | +10.0% |
| Fortis Healthcare Ltd. | ₹58,283 Cr | 55.1 | 11.01% | ₹2,735 Cr | -15.0% |
| Global Health Ltd (Medanta) | ₹38,422 Cr | 69.7 | 15.03% | ₹1,469 Cr | +22.9% |
| Narayana Hrudayalaya Limited | ₹37,907 Cr | 46.2 | 19.85% | ₹2,844 Cr | +5.4% |
| Krishna Institute Of Medical Science (KIMS) | ₹29,056 Cr | 120.6 | 9.72% | ₹1,344 Cr | +13.5% |
| Gujarat Kidney & Super Speciality Limited | ₹1,233 Cr | 62.8 | 6.60% | ₹38 Cr | — |
Listed by market capitalisation. Ratios are shown for context only.
Gujarat Kidney & Super Speciality Limited is trading at ₹150.54, with a market capitalisation of ₹1,233 Cr.
Gujarat Kidney & Super Speciality Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Facilities > Hospitals and Healthcare Centers).
Gujarat Kidney & Super Speciality Limited has a P/E of 62.8 and a return on equity of 6.60%.
Gujarat Kidney & Super Speciality Limited is listed on the NSE under the symbol GKSL and on the BSE under the scrip code 544666.
In Q2 FY27, Gujarat Kidney & Super Speciality Limited reported revenue of ₹38 Cr and net profit of ₹7 Cr, with basic EPS of ₹0.74 (consolidated, parsed from the company's exchange filing).
Gujarat Kidney & Super Speciality Limited reported revenue of ₹38 Cr in Q2 FY27, up 194.6% from ₹13 Cr in Q2 FY26 and up 11.1% from ₹34 Cr in Q1 FY27.
Promoters held 71.45% of Gujarat Kidney & Super Speciality Limited's shares as of Sept 2026, unchanged from Dec 2025.
Data as of 19 Nov 2026. Descriptive market data only — not investment advice.